deltatrials
Completed PHASE2 NCT02368886

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Sponsor: Academic and Community Cancer Research United

Updated 29 times since 2017 Last updated: Jun 3, 2025 Started: Mar 27, 2015 Primary completion: Sep 1, 2017 Completion: Mar 2, 2023

Listed as NCT02368886, this PHASE2 trial focuses on Colon Adenocarcinoma and Rectal Adenocarcinoma and remains completed. Sponsored by Academic and Community Cancer Research United, it has been updated 29 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

29 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Jul 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

Show 24 earlier versions
  1. Apr 2023 — Aug 2023 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  2. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: CompletedActive Not Recruiting

  12. Jan 2020 — Feb 2020 [monthly]

    Completed PHASE2

  13. Dec 2019 — Jan 2020 [monthly]

    Completed PHASE2

  14. Aug 2019 — Dec 2019 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  15. Jun 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  16. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  17. Mar 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  18. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  19. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  20. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  21. Aug 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  22. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  23. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  24. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States, Buffalo, United States, Columbus, United States, Danville, United States, East Syracuse, United States, Green Bay, United States, Kingsport, United States, Los Angeles, United States, Marshfield, United States, Omaha, United States and 11 more location s